#8
Live Biotherapeutic Products and Microbiome Medicine
The gut microbiome is linked to obesity, autoimmune diseases, depression, and cancer treatment response. Live Biotherapeutic Products deliver specific microbial strains at therapeutic doses. The FDA approved Vowst for C. diff in 2023 as the first microbiome therapeutic. By 2030 the microbiome therapeutics pipeline is projected to exceed 200 active clinical trials targeting conditions from mental health to metabolic disease.
0
Photos (1)
Comments on "Live Biotherapeutic Products and Microbiome Medicine"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.